Levosimendan Carinopharm

Levosimendan, the active ingredient in Levosimendan Carinopharm, is a calcium sensitizer presented as an intravenous solution for intravenous use. It is employed in the management of acute decompensated heart failure to improve cardiac output in patients with severe left ventricular dysfunction and to support hemodynamic stability.

GNH USA supplies Levosimendan Carinopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, pharmacies and clinics worldwide with a focus on quality and regulatory compliance through robust cold‑chain logistics where required.

Levosimendan is a calcium sensitizer used in the treatment of acute decompensated heart failure. - Acute decompensated heart failure: improves cardiac output and reduces symptoms of congestion. - Cardiogenic shock: provides inotropic support when conventional agents are insufficient. - Post‑cardiac surgery low cardiac output: enhances myocardial contractility and facilitates weaning from mechanical support.

Levosimendan may be associated with several adverse reactions.

Common Side Effects: - Hypotension: reduction in blood pressure, especially during infusion. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Dizziness: transient light‑headedness. - Flushing: warm sensation and reddening of skin. - Arrhythmias: occasional premature beats.

Serious or Rare Side Effects: - Severe hypotension: may require vasopressor support. - Ventricular tachycardia: potentially life‑threatening rhythm disturbance. - Myocardial ischemia: chest pain due to reduced coronary perfusion. - Allergic reactions: rash, pruritus, or anaphylaxis. - Liver enzyme elevation: abnormal hepatic function tests.

Levosimendan should be used with careful clinical monitoring. - Cardiovascular monitoring: continuously observe blood pressure and heart rate during infusion. - Renal impairment: use cautiously in patients with severe renal dysfunction. - Hepatic impairment: consider dose adjustment or close monitoring in liver disease. - Electrolyte disturbances: correct hypokalemia and hypomagnesemia before administration. - Concomitant vasodilators: avoid excessive hypotension when combined with other vasodilators. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan may interact with several medicines; awareness of major and moderate interactions is essential.

Major Interactions (Avoid): - Sodium nitroprusside: additive hypotensive effect. - Other vasodilators: risk of severe hypotension. - Beta‑blockers: may blunt the intended inotropic response. - Calcium channel blockers: increased risk of arrhythmias.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate electrolyte shifts. - ACE inhibitors: monitor blood pressure closely. - Digoxin: observe for arrhythmic events.